Publication
Government Investigations in Singapore 2025
We have contributed the Singapore chapter of Getting the Deal Through, Government Investigations 2025.
Author:
Global | Publication | December 2016
A recent Federal Court costs decision demonstrates a sustained trend by the court to award meaningful costs awards in patent cases.
The recent decision to award lump-sum costs at the high end of Column IV of Tariff B in Eli Lilly Canada Inc v Hospira Healthcare Corporation, 2016 FC 1218 rounds out a year that has seen the Federal Court grant several meaningful costs awards in patent cases. In this decision, Justice Barnes wrote that the award was meant to be a reasonable contribution to the costs of litigation, citing the complex nature of the proceeding as the basis for deviating from the default award at Column III under the Federal Courts Rules.1
2016 began with a large award of $6.5 million as a lump sum to the plaintiff in Dow Chemical Company v Nova Chemicals Corporation, 2016 FC 91. The total included $2.9 million for legal fees and $3.6 million for disbursements, and amounted to 30% of Dow’s legal fees. Justice O'Keefe based the award on the complexity of the case (see our earlier article on this decision for further details).
Three subsequent decisions in proceedings under the Patented Medicines (Notice of Compliance) Regulations, awarded costs from Column IV or V.2 Additionally, Justice Manson granted a lump-sum award in excess of the default scale following two unsuccessful motions brought by the plaintiff in a medical device infringement proceeding (see our earlier analysis for further details).
Looking forward, the costs awards in 2016 signal a trend that the Federal Court will grant meaningful costs awards in patent cases, recognizing that the default award is unlikely to properly reflect the complexity of the proceedings and the corresponding amount of work required.
1 Federal Courts Rules, SOR/98-106, r 407.
2 Gilead Sciences, Inc v Canada (Health), 2016 FC 856; Gilead Sciences, Inc v Canada (Health), 2016 FC 857; Leo Pharma Inc v Teva Canada Limited, 2016 FC 107; Gilead Sciences, Inc v Canada (Health), 2016 FC 870.
Publication
We have contributed the Singapore chapter of Getting the Deal Through, Government Investigations 2025.
Publication
The private credit market and direct lending have grown and diversified immensely in the past decade, offering alternative sources and terms of debt compared to those historically provided by the syndicated leveraged loan and public issuance markets. Consequently, they are fast becoming pivotal components in the capital ecosystem, so much so that the Bank of England consider that the private credit market is currently responsible for approximately $1.8 trillion of debt issuance, which is four times its size in 2015. This growth has been particularly pronounced in Europe and the US but there has also been significant activity in Asia.
Publication
The EU’s Artificial Intelligence Regulation, commonly referred to as the AI Act, is expected to come into force during the summer of 2024 (the AI Act). The AI Act will be the first comprehensive legal framework for the use and development of artificial intelligence (AI), and is intended to ensure that AI systems developed and used in the EU are safe, transparent, traceable, non-discriminatory and environmentally friendly.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023